Despite some of the proven benefits of voice recognition software, some radiologists still struggle to fit the software into their workflow. Here are some tips from some top VR developers.
Despite some of the proven benefits of voice recognition software, some radiologists still struggle to fit the software into their workflow. Here are some tips from some top VR developers.
1. Designate a champion. Just as with other major technology implementations, your department or practice should have a strong leader that believes in the software and sees its benefits, said GE Healthcare product manager Tim Kearns. That person can really help drive adoption.
2. Take stock of your radiologists and workflow before implementing. “Think through a change management plan,” said Jacques Gilbert, global marketing manager for radiology for GE Healthcare. And make sure you’ve communicated to the entire department or practice just why you’re making the transition.
3. Consider two waves of adopters. Assess who might be less inclined to jump on the VR bandwagon, and who might want to hang on to the transcriptionist for a bit longer. Then graduate the less inclined after the first group has proven the software’s success. Benchmarking their improved turnaround time might add a bit of peer pressure to encourage those who are dragging their feet, Gilbert said.
Cadet agreed with a phased in approach. “For an organization that keeps a transcriptionist on board, you can ease into it. Have some do it, others not, and in time the others will often make their way into it,” he said.
4. Don’t fear the technology. M*Modal’s Don Fallati encouraged radiologists not to be daunted by past experiences with the technology or old horror stories. “The amount of physician training and enrollment are much quicker than they ever were in the past,” he said.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.